EUR/USD 1.17359
0.003%
Gold 3644.12
0.279%
Oil 62.263
0.402%
USD/JPY 147.580
0.248%
GBP/USD 1.35611
-0.088%
GBP/JPY 200.143
0.176%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
On September 13th, the U.S. National Highway Traffic Safety Administration (NHTSA) announced that Volvo Cars will recall 1,355 2026 model year XC90 MHEV, XC60 MHEV, V90CC MHEV, and V60CC MHEV vehicles. The recall is due to a possible damage to the torsion bar in the front seatbelt retractors during production. Dealers will replace both front seatbelt retractors free of charge.On September 13, Zhijie Automobile officially announced that the first batch of deliveries of the new Zhijie R7 and Zhijie S7 officially started at the Zhijie Super Factory.On September 13, Robert Kaplan, vice president of Goldman Sachs Group, said that investors are beginning to question whether they have invested too much money in the United States, and more and more financial institutions are looking to Europe and Asia for growth opportunities. Kaplan said on Friday that some investors are considering whether they should start hedging the US dollar to protect against exchange rate fluctuations. "What has happened since January is that people are still optimistic about the United States, but they are starting to say: I think our allocation to the United States is too high." Kaplan said. "We are having hedging conversations with people around the world, and some of them have never hedged the US dollar in the past 15 years." Kaplan pointed out that although investors still regard the United States as a safe haven for funds, "they have a little more confusion about the US institutional framework."Russian Ministry of Defense: Air defense systems shot down 42 Ukrainian drones in the early hours of Saturday morning.1. The three major U.S. stock indices closed mixed, with the Dow Jones Industrial Average down 0.59%, the S&P 500 down 0.05%, and the Nasdaq up 0.44%, hitting new all-time highs. Merck and Sherwin-Williams fell over 2%, leading the Dow lower. The Wind S7 Index rose 1.14%, with Tesla up over 7% and Apple up over 1%. Chinese concept stocks saw mixed results, with JinkoSolar up over 6% and Douyu down over 4%. 2. U.S. Treasury yields rose across the board, with the 2-year Treasury yield up 0.99 basis points to 3.549%, the 3-year Treasury yield up 1.94 basis points to 3.527%, the 5-year Treasury yield up 3.81 basis points to 3.633%, the 10-year Treasury yield up 4.57 basis points to 4.070%, and the 30-year Treasury yield up 2.69 basis points to 4.681%. 3. International precious metal futures generally closed higher. COMEX gold futures rose 0.19% to $3,680.70 per ounce, a weekly gain of 0.75%. COMEX silver futures rose 1.26% to $42.68 per ounce, a weekly gain of 2.71%. 4. International oil prices rose slightly. The main contract for US crude oil closed up 0.37% at $62.60 per barrel, a weekly gain of 1.18%. The main contract for Brent crude oil rose 0.77% to $66.88 per barrel, a weekly gain of 2.11%. 5. London base metals rose across the board, with LME zinc futures up 1.93% at $2,956.00/ton, up 3.32% for the week; LME nickel futures up 1.52% at $15,380.00/ton, up 0.95% for the week; LME lead futures up 1.13% at $2,019.00/ton, up 1.71% for the week; LME aluminum futures up 1.03% at $2,701.00/ton, up 3.86% for the week; LME tin futures up 0.74% at $34,955.00/ton, up 1.87% for the week; and LME copper futures up 0.13% at $10,064.50/ton, up 1.69% for the week.

U.S. Restricts Use of J&J's COVID Vaccine Due to Risk of Blood Clots

Charlie Brooks

May 06, 2022 09:38

J2.png


The US Food and Drug Administration said on Thursday that it will restrict adult use of Johnson & Johnson's (NYSE:JNJ) COVID-19 vaccination owing to the danger of a rare blood clotting condition, the latest setback for the injection that has been supplanted by competitors.


The J&J shot, which was cleared for adult use in the United States in February 2021, may be used in situations when permitted or approved COVID-19 vaccinations are unavailable or if an user is averse to receiving the other two doses, the Food and Drug Administration said.


J&J is one of three vaccinations that are now in use in the United States. The remaining two are from Moderna (NASDAQ:MRNA) and Pfizer, respectively (NYSE:PFE).


The vaccine manufacturer said that it has amended the COVID-19 vaccination information sheet for the United States to include a warning regarding the risk of thrombosis associated with thrombocytopenia syndrome (TTS), an uncommon but potentially fatal illness.


In high-income nations, use of the J&J shot has been limited, owing to reports of rare, possibly fatal blood clots, manufacturing difficulties, including an unintentional component mix-up by a contract manufacturer, and doubts about effectiveness.


The manufacturer revised its projection for COVID-19 vaccine sales last month, citing a supply glut.


TTS, which is characterized by blood clots and a low platelet count, has previously been documented in recipients of the J&J vaccination.


The FDA changed the information sheet for the J&J vaccine in January to reflect the risk of immune thrombocytopenia, after months of similar action by the European Union's medicines authority.


The FDA stated Thursday that after conducting a study into reported instances, the risk of TTS justified restricting the use of the single-dose injection.


In December, the US Centers for Disease Control and Prevention suggested that Americans take mRNA doses from Pfizer or Moderna rather than J&J's vaccination owing to the possibility of blood clotting.


According to the CDC, about 18.7 million Americans got a J&J COVID-19 injection, compared to 217.5 million who received the Moderna vaccination and 340.6 million who received the Pfizer shot.

Suggestion